Core Insights - The announcement from Hutchison China MediTech (和黄医药) indicates the completion of patient enrollment for the SANOVO Phase III study, which evaluates the combination therapy of Savolitinib (沃瑞沙) and Osimertinib (泰瑞沙) for specific non-small cell lung cancer patients with EGFR mutations and MET overexpression [1] Group 1 - The SANOVO study is a randomized, controlled clinical trial assessing the efficacy and safety of the combination therapy compared to the standard monotherapy of Osimertinib [1] - The primary endpoint of the study is progression-free survival (PFS) as assessed by investigators, with secondary endpoints including independent review committee-assessed PFS, overall survival (OS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), time to response (TTR), and safety [1] - Topline results from the SANOVO study are expected to be announced in the second half of 2026, followed by submission of results to relevant academic conferences [1] Group 2 - Savolitinib is a potent and highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and Hutchison China MediTech, while Osimertinib is an irreversible third-generation EGFR TKI [2]